Trade: FDA approves Daraxonrasib this year?

Market context

Revolution Medicines' daraxonrasib, a RAS inhibitor targeting RAS-mutated cancers, faces an FDA approval decision within the next two years. The 61% implied probability on Polymarket's order book reflects meaningful uncertainty about whether the company will secure full or conditional approval by year-end 2026. RAS mutations occur across multiple cancer types, making this a potentially significant therapeutic category if clinical evidence supports efficacy and safety profiles acceptable to regulators.

RAS inhibitor development has historically faced technical hurdles. Sotorasib (Lumakras), approved in 2021 for KRAS G12C-mutated lung cancer, took roughly a decade from discovery to FDA clearance and initially showed modest response rates. Adagrasib, another KRAS inhibitor, followed in 2023. These precedents suggest regulatory pathways exist for RAS-targeted drugs, though approval timelines remain unpredictable and clinical trial results determine advancement. Daraxonrasib's broader target profile—covering multiple RAS mutations rather than single variants—introduces both opportunity and additional regulatory scrutiny.

Key catalysts include interim or final trial data releases, which typically drive material repricing on prediction markets. Revolution Medicines' clinical programme timeline and any FDA feedback letters will signal approval likelihood. Recent oncology approvals have accelerated for drugs addressing high unmet needs with compelling efficacy data, though regulatory standards remain rigorous. Traders should monitor company earnings calls and clinical conference presentations (ASCO, ESMO) for trial updates. The two-year settlement window provides adequate time for Phase 2 or Phase 3 readouts, but execution risk remains substantial given the competitive RAS inhibitor landscape.

How this market resolves

Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a two-hour dispute window opens, and if no one stakes a counter-claim the payout is final. Contested outcomes escalate to UMA token-holder voting. Payouts clear in USDC to the winning side.

How to trade this market step by step

The mechanics for trading "FDA approves Daraxonrasib this year?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.

1. Sign in on polygram.ink with your email — no full KYC under $1,500 lifetime trading volume.
2. Deposit USDC on Polygon (lowest fees, ~$0.01 per transaction) or Ethereum. Funds credit after 12 confirmations.
3. Pick a side. Buy YES if you believe the event will happen; buy NO if you think it won't. The current YES price reflects the market's collective probability.
4. Size your position. If you stake 100 USDC at 62% YES, you'll receive shares that pay $161 if YES resolves true — a 61% gross return. If NO resolves, your shares are worth $0.
5. Set risk controls (optional). Stop-loss, take-profit, and limit-order types all supported. Use the trade ticket's slippage box to cap your maximum entry price.
6. Wait for resolution. When the event resolves on-chain via the UMA optimistic oracle, the winning side settles to 100¢ automatically and USDC hits your balance within seconds. Withdrawable to any wallet you control.

How active is this market?

$0 in lifetime turnover and $539 of resting liquidity puts this market in the below the median by volume for drug contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.

The market has been open for under a month — fresh enough that information asymmetry remains a real factor.

Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.

Key terms

YES / NO share

A binary outcome token that pays $1.00 if the underlying claim resolves true (YES) or false (NO), and $0 otherwise. The market price between 0¢ and 100¢ is the implied probability.

CLOB

Central limit order book. The matching engine that pairs YES buyers with NO buyers (effectively the same trade). Polymarket's CLOB on Polygon executes trades on-chain via the conditional-tokens framework.

Liquidity

USDC capital sitting in resting limit orders inside the order book. Deeper liquidity means smaller slippage on large trades and a tighter bid-ask spread.

UMA optimistic oracle

The on-chain dispute system that settles each Polymarket market. A proposer submits the outcome, a two-hour challenge window opens, and unchallenged proposals finalise the resolution.

Slippage

The difference between the displayed mid-price and your fill price. Affects market orders most; limit orders avoid slippage but may take time to fill.

Conditional token

ERC-1155 outcome share issued by Gnosis Conditional Tokens on Polygon. The token type that resolves to $1.00 or $0.00 at settlement.

See the full prediction-market glossary →

Frequently asked questions

Risk and regulatory note

Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.

Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.

Related prediction markets

Explore more prediction market odds and trading opportunities on PolyGram:

• All drug prediction markets
• How prediction markets work
• Browse all prediction markets on PolyGram
• Top prediction market traders
• Back to PolyGram home